Leveraging Targeted Protein Degradation for G Protein-Coupled Receptors: The Development of CCR2 Molecular Degraders
Year: 2025
Type: article
Language: en
Topic: Protein Degradation and Inhibitors
Authors and affiliations:
raw_author_name: Khaled Essa
raw_affiliation_strings: Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands
raw_author_name: Natalia V. Ortiz Zacarías
raw_affiliation_strings: Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands
raw_author_name: Sascha Roth
raw_affiliation_strings: R&D, AstraZeneca
Safety Innovation and PROTAC Safety, Clinical Pharmacology & Safety Sciences
Safety Innovation and PROTAC Safety, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0SL, United Kingdom
raw_author_name: Bo-Tao Xin
raw_affiliation_strings: Department of Cell and Chemical Biology, Chemical Immunology
Leiden University Medical Centre
Department of Cell and Chemical Biology, Chemical Immunology, Leiden University Medical Centre, Leiden 2333 ZC, The Netherlands
raw_author_name: Sabine de Winter
raw_affiliation_strings: Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands
raw_author_name: Cas van der Horst
raw_affiliation_strings: Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands
raw_author_name: Bente Bleijs
raw_affiliation_strings: Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands
raw_author_name: Richard A. de Heiden
raw_affiliation_strings: Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands
raw_author_name: Rodanthi Voulgaraki
raw_affiliation_strings: Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands
raw_author_name: Elsa Neubert
raw_affiliation_strings: Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands
raw_author_name: Huib Ovaa
raw_affiliation_strings: Department of Cell and Chemical Biology, Chemical Immunology
Leiden University Medical Centre
Department of Cell and Chemical Biology, Chemical Immunology, Leiden University Medical Centre, Leiden 2333 ZC, The Netherlands
raw_author_name: Erik H. J. Danen
raw_affiliation_strings: Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Division of Cell Systems and Drug Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands
raw_author_name: Monique P. C. Mulder
raw_affiliation_strings: Department of Cell and Chemical Biology, Chemical Immunology
Leiden University Medical Centre
Department of Cell and Chemical Biology, Chemical Immunology, Leiden University Medical Centre, Leiden 2333 ZC, The Netherlands
raw_author_name: Kevin Moreau
raw_affiliation_strings: R&D, AstraZeneca
Safety Innovation and PROTAC Safety, Clinical Pharmacology & Safety Sciences
Safety Innovation and PROTAC Safety, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0SL, United Kingdom
raw_author_name: Daan van der Es
raw_affiliation_strings: Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands
raw_author_name: Laura H. Heitman
raw_affiliation_strings: Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR)
Leiden University
Oncode Institute
Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden 2333 CC, The Netherlands